Gastroenterologists seeking better outcomes than Humira and Remicade for Crohn's disease

26 September 2016
2019_biotech_test_vial_discovery_big

In a market long dominated by AbbVie's (NYSE: ABBV) Humira (adalimumab) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Remicade (infliximab), practice patterns are shifting and novel pipeline agents will introduce a new treatment paradigm in Crohn's disease.

In a recent study conducted by Spherix Global Insights, US gastroenterologists (n=90) describe changes in patient management, largely including the increased use of Entyvio (vedolizumab), from Takeda Pharmaceutical (TYO: 4502) and a more aggressive approach with biologics overall. But it doesn't stop there; more than 70% of the surveyed gastroenterologists agree that there is a high need for new biologics for IBD.

Even though the group reports higher satisfaction with biologics compared to other drug classes, there is still ample room for improvement. According to one respondent, "None of the medications work over 60% of the time to get remission. Patient compliance, side effects and, as always, cost" represent big challenges for physicians…and big opportunities for newcomers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology